Kymab peer-reviewed research published on 30 September 2020 in Cancer Immunology Research (a journal of the American Association for Cancer Research) demonstrates that KY1044, Kymab’s fully human anti-ICOS antibody, increases intratumoural cytotoxic to regulatory T cell ratio and induces tumour regression.
In this September 2020 Lancet Microbe commentary, Kymab scientists and colleagues explore how monoclonal antibodies could support efforts to prevent or treat antimicrobial resistant bacteria infections in intensive care settings.
At the American Association for Cancer Research (AACR) Virtual Annual Meeting in June 2020, Kymab researchers presented data using their anti ICOS antibody that suggests that high content of Tregs expressing ICOS in the tumour microenvironment is associated with poorer survival in patients with hepatocellular carcinoma.
At the American Association for Cancer Research (AACR) Virtual Annual Meeting in June 2020, Kymab researchers presented data showing that KY1043, a novel CD25-directed PD-L1 IL-2 immunocytokine, provides targeted immune checkpoint inhibition coupled with dose-dependent anti-tumour activity.
Research published in Blood on 21 May 2020 demonstrates that KY1070, Kymab’s fully human anti-BMP6 antibody reduces the need for erythropoietin in rodent models of the Anaemia of Chronic Disease. Effects are seen - either as monotherapy or in combination with Darbepoetin alfa - on iron metabolism and anaemia resolution.
At the American Society of Hematology 61st Annual Meeting on December 8, 2019 in Orlando, Florida, Kymab Senior Research Scientist Dr John Blackwood, presented data showing that KY1049, a Factor VIII mimetic bispecific antibody, functionally rescues Factor VIII deficiency ex vivo.
At the American Society of Hematology 61st Annual Meeting on December 9, 2019 in Orlando, Florida, Kymab Research Scientist Dr Matthew Wake presented new findings on KY1066, a first-in-class, fully human antibody targeting the enzymatic activity of matriptase-2 for the treatment of iron overload diseases, such as β thalassemia.
Research published on Friday 15 November 2019 in Nature Communications from the University of Sheffield’s Department of Infection, Immunity and Cardiovascular Disease shows that treatment with a specific Kymab antibody can potentially reverse the process behind the development of Pulmonary Arterial Hypertension or PAH. The authors state that targeting "with a therapeutic antibody is a potential treatment strategy in PAH”.
At the Society of Immunotherapy for Cancer (SITC) 34th Annual Meeting in National Harbor, Maryland on Friday 8 November, 2019, Kymab Senior Research Scientist Cassie Van Krinks presents data showing that targeting PD-L1 and the IL-2 receptor with KY1043 is a valid approach for inducing a strong anti-tumor immune response.
At the European Congress on Thrombosis and Haemostasis (ECTH) in Glasgow, UK on October 3, 2019, Kymab Senior Research Scientist, Dr John Blackwood, outlined the development and preclinical evaluation of KY1049, the Company’s fully human Factor VIII (FVIII)-mimetic bispecific antibody.
At the Fifth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CICON) in Paris, September 27, 2019, Dr Richard Sainson, Kymab’s Senior Director, Translational Medicine, presented positive new findings for Kymab’s KY1044 Anti-ICOS Programme.
Kymab researchers have deposited a preprint publication at Biorxiv describing KY1044 preclinical data and entitled "A novel antibody targeting ICOS increases intratumoural cytotoxic to regulatory T cell ratio and induces tumour regression". The expanding data set strengthens evidence for a dual mechanism of action of KY1044: the study shows that a targeted approach can be used to exploit differential ICOS expression patterns, allowing depletion of ICOShigh TReg cells, agonism of ICOSlow TEff cells and an overall increase in the TEff:TReg ratio in the tumour microenvironment. This shift in the immune contexture resulted in a strong and long lasting anti-tumour response.
At the 24th World Congress of Dermatology in Milan, June 10-15, 2019, Kymab’s Senior Medical Director Dr Porter-Brown presented data showing that Kymab’s novel anti-OX40L monoclonal antibody, with potential in atopic dermatitis, demonstrates acceptable safety and tolerability profiles. The results support development of KY1005 in immune-mediated diseases, such as AD, and a phase 2a study is under way.
At the 24th World Congress of Dermatology in Milan, June 10-15, 2019, Kymab’s Senior Medical Director Dr Porter-Brown presented data showing that Kymab’s OX40L-blocking monoclonal antibody KY1005 strongly suppresses the delayed-type hypersensitivity skin response to KLH in healthy volunteers. A phase 2a study in moderate to severe atopic dermatitis is under way.
At the 24th European Hematology Association’s Annual Congress 2019 in Amsterdam, Netherlands, June 15, Kymab will deliver an oral presentation on pre-clinical evaluation of KY1049, Kymab’s proprietary FVIII mimetic antibody Abstract: S851
At the 24th European Hematology Association’s Annual Congress 2019 in Amsterdam, Netherlands, June 14, Kymab will present a poster on development of KY1049 using Kymab’s proprietary Intelliselect Bispecific Platform which can efficiently generate diverse and extensive panels of fully human, common light chain bispecific antibodies. Abstract: PF338 at https://library.ehaweb.org/.
At the June 2019 American Society of Clinical Oncology (ASCO) Kymab presented a poster and had an abstract on an ongoing first-in-human study of KY1044, a fully human anti-ICOS IgG1 antibody as monotherapy and in combination with atezolizumab in patients with selected advanced malignancies.
At the April 2019 European Laboratory Research & Innovation Group (ELRIG) – Research & Innovations, Kymab presented data on the development of innovative assays for testing of our therapeutic antibodies, including work conducted using macrophage-like cell lines for high-throughput screening of molecules able to modulate macrophage function.
At the April 2019 European Laboratory Research & Innovation Group (ELRIG) – Research & Innovations, Kymab presented results describing the development of an imaging-based T-cell infiltration assay, a model that can be multiplexed with tumour killing and activation as readouts and has the potential to be used to screen drug candidates while enabling a better understanding of the complex biology of the tumour microenvironment.
At the April 2019 American Association for Cancer Research Annual meeting, Kymab translational science activities reveal solid tumours, such as oesophageal cancer, cervical cancer, non-small cell lung cancer and others, that are infiltrated with high numbers of ICOS-positive regulatory T-cells. The combination of transcriptomic analysis and IHC can be used to differentiate such tumours: KY1044 is in phase 1/2 study assessing its safety and efficacy as a single agent and in combination.
Published in Nature Metabolism on 7 January 2019, the paper by Professor Igor Theurl, Kymab's Co-Head of Haematology, together with scientists at Dresden University, describes how the Transferrin receptor 2 controls bone mass and pathological bone formation via BMP and Wnt signalling.
At the December 2018 American Society of Hematology Conference Kymab, together with Collaborators from the Department of Internal Medicine at the University of Innsbruck, presented data that showed that anti-BMP6 antibody KY1070 worked synergistically with erythropoietin in two different models of anaemia of chronic disease
Published in The Journal of Infectious Disease on 30 October 2018, the article 'Anatomic and Cellular Niches for Mycobacterium tuberculosis in Latent Tuberculosis Infection' by Stephen Reece, PhD, Kymab's Group Leader, Infectious Diseases and Vaccines, together with other scientists, evaluates literature on M. tuberculosis locations during latency.
At the April 2018 American Association for Cancer Research Annual meeting, Kymab's team show that combining immune checkpoint blockers with the anti-ICOS KY1044 antibody results in a strong tumour response, warranting the assessment of KY1044 in cancer patients in a clinical trial
Kymab's data reports that KY1055, a novel ICOS/PD-L1 bispecific antibody, efficiently enhances T cell activation and delivers a potent anti-tumour response in vivo: the results, presented at the April 2018 American Association for Cancer Research Annual meeting, support development of KY1055 for the treatment of solid tumours
Kymab's data at the November 2017 Society for Immunotherapy of Cancer meeting on its lead immuno-oncology antibody KY1044, showing strong potential for inhibiting tumour growth
View the poster
2017 British Society for Immunology Congress poster showing that T-cells generated by Kymab's co-culture system can provide a suitable setting for evaluation of potential patient responses to immunotherapy
At the 2017 British Society for Immunology Congress, Kymab's team describe a cell-based, in vitro screening cascade to characterise anti-human PD-L 1 antibodies, identifying a lead clone, KY1003, that has the attributes of a clinically relevant PD-L1 antibody
The Kymab team developed a "tumour-educated" T-cell killing assay for predictive in vitro assessment of anti-PD-L1 antibodies: data presented at the 2017 British Society for Immunology Congress shows how KY1003 can revert T-cell exhaustion in in vitro models.
Kymab published a report in Nature Biotechnology in March 2014 showing the engineering of mice with the full set of human antibody genes. These mice can produce an enormous range of human antibodies, which can be developed as potent drugs to treat a variety of human diseases such as cancer, autoimmune and infectious diseases.
On 20 September 2017, Kymab and Seattle Children’s Research Institute published impressive results in Science Translational Medicine using KY1005 in a model of acute Graft-versus-Host Disease (aGVHD), suggesting an important role in blood-system transplants, such as in the treatment of leukaemia.